Theravance Inc (THRX.OQ)

THRX.OQ on NASDAQ Stock Exchange Global Select Market

22.76USD
20 Aug 2014
Price Change (% chg)

$-0.54 (-2.32%)
Prev Close
$23.30
Open
$23.17
Day's High
$23.31
Day's Low
$22.73
Volume
129,009
Avg. Vol
365,228
52-wk High
$34.52
52-wk Low
$20.23

THRX.OQ

Chart for THRX.OQ

About

Theravance, Inc. (Theravance) is a biopharmaceutical company with a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies. The Company is focused on the discovery, development and commercialization of small molecule medicines across a number of therapeutic areas including... (more)

Overall

Beta: 1.75
Market Cap (Mil.): $2,679.83
Shares Outstanding (Mil.): 115.01
Dividend: 0.25
Yield (%): 4.29

Financials

  THRX.OQ Industry Sector
P/E (TTM): -- 32.90 33.74
EPS (TTM): -1.23 -- --
ROI: -23.97 18.79 18.03
ROE: -- 19.42 18.77
Search Stocks

BRIEF-GSK and Theravance says gains approval in Japan for Anoro Ellipta

* Press_release:anoro ellipta(umeclidinium/vilant erol) gains approval in Japan for the treatment of COPD

04 Jul 2014

BRIEF-GSK, Theravance submit sNDA to U.S. FDA for Breo Ellipta

* GSK and Theravance announce submission to US regulatory authorities for Fluticasone Furoate/Vilanterol in asthma

30 Jun 2014

BRIEF-GSK, Theravance say positive FF/VI phase III study to support filing in Japan

* GSK & Theravance announce phase III study of FF/VI in COPD commenced to support potential future filing in Japan

22 Apr 2014

Competitors

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Pechala's Reports
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks